“We will continue doing what we do best -- find new therapeutics to solve this crisis. Let’s all focus on this mission and not politics.” – Dr. Jeremy Levin, Biocentury Scientists and researchers at America’s biopharmaceutical companies are working around the clock to develop vaccines,…

Day #2 of the BIO CEO & Investor Conference was all about the future. How can we ensure the workforce reflects the diverse demographics of the patients the industry serves? What does the future of biotech investment look like? How can we incentivize innovation? Here are some takeaways from …

We’re seeing an “extraordinary level” of biotech innovation, said BIO Chair Jeremy Levin, CEO of Ovid Therapeutics Inc., while kicking off the 22nd BIO CEO & Investor Conference on February 10th in New York. Day #1 of the conference featured discussions about the breakthrough therapies of the…

“The promise for patients has never been better from a scientific point of view,” said BIO CEO and former Member of Congress Jim Greenwood, speaking at the 22nd BIO CEO & Investor Conference in New York. “But it’s the worst of times politically.” Specifically: There are “mountains of political…

The 22nd annual BIO CEO & Investor Forum kicked off today with a Welcome and Update on BIO's 2020 Initiatives on Behalf of the Industry given by Jeremy Levin, CEO of Ovid Therapeutics Chair of the Board of Directors of BIO. The industry was established in 1970’s during an era of bipartisan…

For nearly two decades, the BIO World Congress has served as a catalyst to the growth and evolution of the bioeconomy. From the conversations started in BIO One-on-One PartneringTM that have led to critical partnerships, to the emerging company presentations that spurred investment, the conference…

For the first time ever, BIO took a comprehensive look at the state of diversity and inclusion in the biotech industry. The findings are in a newly released report, “Measuring Diversity in the Biotech Industry: Building an Inclusive Workforce.”  Image …

Jennifer Bright with the Innovation and Value Initiative recently wrote for Morning Consult that the U.S. is “engaged in the challenging but important conversation about how to assess the value of pharmaceuticals.”  It’s a conversation that should be transparent and open to everyone,…

This week, Congress is expected to consider a USMCA trade agreement that does NOT include stronger IP protections for American innovators who develop biologic medicines. While the removal of these provisions is being hailed as a defeat for Big Pharma, here are three key points to keep in mind as…